Nevro Corp. (NVRO)
NYSE: NVRO · IEX Real-Time Price · USD
8.35
-0.26 (-3.02%)
Jul 2, 2024, 4:00 PM EDT - Market closed
Nevro Revenue
Nevro had revenue of $430.75M in the twelve months ending March 31, 2024, with 3.83% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $101.90M with 5.78% year-over-year growth. In the year 2023, Nevro had annual revenue of $425.17M with 4.63% growth.
Revenue (ttm)
$430.75M
Revenue Growth
+3.83%
P/S Ratio
0.71
Revenue / Employee
$354,523
Employees
1,215
Market Cap
306.68M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 425.17M | 18.81M | 4.63% |
Dec 31, 2022 | 406.37M | 19.46M | 5.03% |
Dec 31, 2021 | 386.91M | 24.86M | 6.87% |
Dec 31, 2020 | 362.05M | -28.21M | -7.23% |
Dec 31, 2019 | 390.26M | 2.97M | 0.77% |
Dec 31, 2018 | 387.29M | 60.62M | 18.56% |
Dec 31, 2017 | 326.67M | 98.17M | 42.96% |
Dec 31, 2016 | 228.50M | 158.90M | 228.28% |
Dec 31, 2015 | 69.61M | 37.03M | 113.69% |
Dec 31, 2014 | 32.57M | 9.07M | 38.61% |
Dec 31, 2013 | 23.50M | 5.35M | 29.48% |
Dec 31, 2012 | 18.15M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
DocGo | 703.37M |
OraSure Technologies | 304.64M |
ADC Therapeutics | 68.62M |
SOPHiA GENETICS | 64.18M |
Foghorn Therapeutics | 33.90M |
C4 Therapeutics | 20.04M |
Verrica Pharmaceuticals | 8.91M |
NVRO News
- 4 days ago - Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08 - PRNewsWire
- 21 days ago - Nevro to Present at Truist Securities MedTech Conference - PRNewsWire
- 7 weeks ago - Nevro to Present at BofA Securities 2024 Healthcare Conference - PRNewsWire
- 2 months ago - Nevro Reports First-Quarter 2024 Financial Results - PRNewsWire
- 2 months ago - Nevro to Report First-Quarter 2024 Financial Results and Host Earnings Conference Call on May 7, 2024 - PRNewsWire
- 4 months ago - Nevro Receives FDA 510(k) Clearance to Use SI Fixation System Without Need to Include Lateral Screw - PRNewsWire
- 4 months ago - Nevro Enters Into Cooperation Agreement With Engaged Capital - PRNewsWire
- 4 months ago - Nevro Reports Fourth-Quarter and Full-Year 2023 Financial Results - PRNewsWire